National Disclosure Summit Offers First Full Conference on Physician Payment Sunshine Act Final Rule

Now that CMS has issued the finalized regulations implementing the Physician Payment Sunshine Act—Section 6002 of the Affordable Care Act—lawyers, stakeholders, and other interested parties are scrambling to analyze and interpret the 287-page final rule.  While attorneys and stakeholders scramble through the pages, interested stakeholders can attend the 5th Annual Summit on Disclosure, Transparency and Aggregate Spend for Drug, Device and Biotech Companies. 

The summit is being held in Washington, DC, between February 19 – 21, 2013.  The three-day agenda is packed with expert panels from the industry and government.  

The Summit will offer pharmaceutical and medical device professionals the first opportunity to assess the Final Rule with the help of senior government regulators, as well as an array of industry experts and leading consultants who have been in the vanguard of building and implementing aggregate spend solutions.  The Summit will also provide a comprehensive update of the rapidly evolving transparency requirements now taking shape across the globe and offer timely advice on creating a global aggregate spend and disclosure program.   

In-house experts will share their experience on a wide array of emerging best practices ranging from project management to building scalability and sustainability. Panels of in-house and outside experts will weigh in on key topics such as drug sample compliance, R&D and clinical trials compliance, Fair Market Value, and advanced operational issues.